Global Hydroxyapatite Market: Key Developments
In March 2022, Cgbio signed a five-year contract worth KRW 10 billion with Kerunxi Medical, a Chinese company specializing in dental equipment, for the export of Bongros Dental, a bone graft material.
In March 2022, The Cgbio signed an export contract with Shanghai Sanyou Medical for KRW 100 billion worth of bone substitute “BONGROS” for five years.
In April 2021, FLUIDINOVA started an R&D project, “FLUIDINOVA - Innovation in Nanocrystalline Hydroxyapatite Offering Synthetics and Industrial/ Organizational Processes.” With this project, the company expands the offer of new products for the pharmaceutical, medical devices, and 3D printing segment.
In January 2021, FLUIDINOVA started a project with INKplant, namely Ink- based Hybrid Multi-material Fabrication of Next Generation Implants. This project will develop an advanced 'toolbox' of technologies to enable 3D printing of tailor-made and is likely to enhance the company's hydroxyapatite business.
Hydroxyapatite Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients